All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence

December 5th 2025

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC

December 5th 2025

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

FDA Approves Liso-Cel for Relapsed/Refractory Marginal Zone Lymphoma

December 4th 2025

The FDA approved liso-cel for relapsed/refractory MZL after 2 prior lines of therapy.

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis

December 4th 2025

Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC

December 4th 2025

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Loncastuximab Tesirine Plus Glofitamab Yields High CR Rates in DLBCL in Updated LOTIS-7 Analysis

December 4th 2025

Adding loncastuximab tesirine to glofitamab led to activity irrespective of disease status in relapsed/refractory diffuse large B-cell lymphoma.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Researchers Find Ancestry Impacts Effectiveness of Prostate Cancer Drugs

December 4th 2025

Effectiveness of prostate cancer drugs potentially tied to ancestry according to new research data.

Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025

December 4th 2025

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

CMS Releases Final CY 2026 Hospital Outpatient Prospective Payment System (OPPS): Implications for Nuclear Medicine

December 3rd 2025

The Centers for Medicare and Medicaid released the final rule for the CY Hospital OPPS, which will take effect in 2026.

FDA Approves Pirtobrutinib for Relapsed or Refractory CLL/SLL

December 3rd 2025

The FDA has granted traditional approval to pirtobrutinib for covalent BTK inhibitor–exposed, relapsed/refractory CLL or SLL.

TARA-002 Intravesical Therapy Generates High CR Rate in BCG-Naive NMIBC With CIS

December 3rd 2025

Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.

Silevertinib Drives CNS Responses in First-Line NSCLC With Non-Classical EGFR Mutations

December 3rd 2025

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

Maintenance Fuzuloparib Displays PFS Benefit in Newly Diagnosed, Advanced Ovarian Cancer

December 3rd 2025

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

Updated FIREFLY-1 Data Further Support Tovorafenib as a SOC in R/R Pediatric Low-Grade Glioma

December 3rd 2025

Tovorafenib produced deep, durable responses in pLGG, with long treatment-free intervals and minimal tumor rebound after therapy.

Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025

December 3rd 2025

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Lutetium Lu 177 Vipivotide Tetraxetan Shows Activity in Oligometastatic HSPC

December 2nd 2025

Lutetium Lu 177 vipivotide tetraxetan was effective in patients with oligometastatic hormone-sensitive prostate cancer.